331 related articles for article (PubMed ID: 37896960)
1. A Recombinant Protein XBB.1.5 RBD/Alum/CpG Vaccine Elicits High Neutralizing Antibody Titers against Omicron Subvariants of SARS-CoV-2.
Thimmiraju SR; Adhikari R; Villar MJ; Lee J; Liu Z; Kundu R; Chen YL; Sharma S; Ghei K; Keegan B; Versteeg L; Gillespie PM; Ciciriello A; Islam NY; Poveda C; Uzcategui N; Chen WH; Kimata JT; Zhan B; Strych U; Bottazzi ME; Hotez PJ; Pollet J
Vaccines (Basel); 2023 Oct; 11(10):. PubMed ID: 37896960
[TBL] [Abstract][Full Text] [Related]
2. Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern.
Pollet J; Strych U; Chen WH; Versteeg L; Keegan B; Zhan B; Wei J; Liu Z; Lee J; Kundu R; Adhikari R; Poveda C; Jose Villar M; Rani Thimmiraju S; Lopez B; Gillespie PM; Ronca S; Kimata JT; Reers M; Paradkar V; Hotez PJ; Elena Bottazzi M
Vaccine; 2022 Jun; 40(26):3655-3663. PubMed ID: 35568591
[TBL] [Abstract][Full Text] [Related]
3. Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern.
Pollet J; Strych U; Chen WH; Versteeg L; Keegan B; Zhan B; Wei J; Liu Z; Lee J; Kundu R; Adhikari R; Poveda C; Villar MJ; Thimmiraju SR; Lopez B; Gillespie PM; Ronca S; Kimata JT; Reers M; Paradkar V; Hotez P; Bottazzi ME
bioRxiv; 2022 Mar; ():. PubMed ID: 34268512
[TBL] [Abstract][Full Text] [Related]
4. A COVID-19 DNA Vaccine Candidate Elicits Broadly Neutralizing Antibodies against Multiple SARS-CoV-2 Variants including the Currently Circulating Omicron BA.5, BF.7, BQ.1 and XBB.
Ding Y; Fan F; Xu X; Zhao G; Zhang X; Zhao H; Wang L; Wang B; Gao XM
Vaccines (Basel); 2023 Mar; 11(4):. PubMed ID: 37112691
[TBL] [Abstract][Full Text] [Related]
5. A recombinant spike-XBB.1.5 protein vaccine induces broad-spectrum immune responses against XBB.1.5-included Omicron variants of SARS-CoV-2.
He C; Alu A; Lei H; Yang J; Hong W; Song X; Li J; Yang L; Wang W; Shen G; Lu G; Wei X
MedComm (2020); 2023 Jun; 4(3):e263. PubMed ID: 37125241
[TBL] [Abstract][Full Text] [Related]
6. A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates.
Liu Z; Zhou J; Wang X; Xu W; Teng Z; Chen H; Chen M; Zhang G; Wang Y; Huang J; Wang Q; Jiang S; Lu L
Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2221713120. PubMed ID: 36897979
[TBL] [Abstract][Full Text] [Related]
7. Kappa-RBD produced by glycoengineered Pichia pastoris elicited high neutralizing antibody titers against pseudoviruses of SARS-CoV-2 variants.
Mi T; Wang T; Xu H; Sun P; Hou X; Zhang X; Ke Q; Liu J; Hu S; Wu J; Liu B
Virology; 2022 Apr; 569():56-63. PubMed ID: 35276485
[TBL] [Abstract][Full Text] [Related]
8. Intranasal Boosting with Spike Fc-RBD of Wild-Type SARS-CoV-2 Induces Neutralizing Antibodies against Omicron Subvariants and Reduces Viral Load in the Nasal Turbinate of Mice.
Cai JP; Luo C; Wang K; Cao H; Chen LL; Zhang X; Han Y; Yin F; Zhang AJ; Chu H; Yuan S; Kok KH; To KK; Chen H; Chen Z; Jin DY; Yuen KY; Chan JF
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992395
[TBL] [Abstract][Full Text] [Related]
9. Immune Evasion of SARS-CoV-2 Omicron Subvariants XBB.1.5, XBB.1.16 and EG.5.1 in a Cohort of Older Adults after ChAdOx1-S Vaccination and BA.4/5 Bivalent Booster.
Machado RRG; Candido ÉD; Aguiar AS; Chalup VN; Sanches PR; Dorlass EG; Amgarten DE; Pinho JRR; Durigon EL; Oliveira DBL
Vaccines (Basel); 2024 Jan; 12(2):. PubMed ID: 38400128
[TBL] [Abstract][Full Text] [Related]
10. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
11. XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants.
Patel N; Trost JF; Guebre-Xabier M; Zhou H; Norton J; Jiang D; Cai Z; Zhu M; Marchese AM; Greene AM; Mallory RM; Kalkeri R; Dubovsky F; Smith G
Sci Rep; 2023 Nov; 13(1):19176. PubMed ID: 37932354
[TBL] [Abstract][Full Text] [Related]
12. Broad protective RBD heterotrimer vaccines neutralize SARS-CoV-2 including Omicron sub-variants XBB/BQ.1.1/BF.7.
Zhang Y; Kang X; Liu S; Han P; Lei W; Xu K; Xu Z; Gao Z; Zhou X; An Y; Han Y; Liu K; Zhao X; Dai L; Wang P; Wu G; Qi J; Xu K; Gao GF
PLoS Pathog; 2023 Sep; 19(9):e1011659. PubMed ID: 37721934
[TBL] [Abstract][Full Text] [Related]
13. Low Neutralizing Activities to the Omicron Subvariants BN.1 and XBB.1.5 of Sera From the Individuals Vaccinated With a BA.4/5-Containing Bivalent mRNA Vaccine.
Nham E; Kim J; Lee J; Park H; Kim J; Lee S; Choi J; Kim KT; Yoon JG; Hwang SY; Song JY; Cheong HJ; Kim WJ; Park MS; Noh JY
Immune Netw; 2023 Dec; 23(6):e43. PubMed ID: 38188597
[TBL] [Abstract][Full Text] [Related]
14. Omicron neutralization character in patients with breast cancer and liver cancer after the nationwide omicron outbreak.
Zhang S; Tang L; Bao C; Wang S; Li B; Huang L; Song H; Fu J; Xu Z; Meng F; Cao L; Gao Y; Yuan Y; Chen Y; Yuan J; Zhou C; Li F; Qin L; Guo Y; Zhang C; Song J; Fan X; Jiang Z; Wang FS; Xu R
Cancer Med; 2024 Jun; 13(11):e7304. PubMed ID: 38826094
[TBL] [Abstract][Full Text] [Related]
15. Serum neutralization of SARS-CoV-2 Omicron BA.2, BA.2.75, BA.2.76, BA.5, BF.7, BQ.1.1 and XBB.1.5 in individuals receiving Evusheld.
Zhao Q; Wang X; Zhang Z; Liu X; Wang P; Cao J; Liang Q; Qu J; Zhou M
J Med Virol; 2023 Jul; 95(7):e28932. PubMed ID: 37403923
[TBL] [Abstract][Full Text] [Related]
16. Defining a de novo non-RBM antibody as RBD-8 and its synergistic rescue of immune-evaded antibodies to neutralize Omicron SARS-CoV-2.
Rao X; Zhao R; Tong Z; Guo S; Peng W; Liu K; Li S; Wu L; Tong J; Chai Y; Han P; Wang F; Jia P; Li Z; Zhao X; Li D; Zhang R; Zhang X; Zou W; Li W; Wang Q; Gao GF; Wu Y; Dai L; Gao F
Proc Natl Acad Sci U S A; 2023 Dec; 120(52):e2314193120. PubMed ID: 38109549
[TBL] [Abstract][Full Text] [Related]
17. Neutralization of SARS-CoV-2 BA.2.86 and JN.1 by CF501 adjuvant-enhanced immune responses targeting the conserved epitopes in ancestral RBD.
Liu Z; Zhou J; Wang W; Zhang G; Xing L; Zhang K; Wang Y; Xu W; Wang Q; Man Q; Wang Q; Ying T; Zhu Y; Jiang S; Lu L
Cell Rep Med; 2024 Mar; 5(3):101445. PubMed ID: 38428429
[TBL] [Abstract][Full Text] [Related]
18. Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children.
Bellusci L; Grubbs G; Sait S; Yonker LM; Randolph AG; Novak T; Kobayashi T; ; Khurana S
Nat Commun; 2023 Dec; 14(1):7952. PubMed ID: 38040697
[TBL] [Abstract][Full Text] [Related]
19. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.
Wang Q; Iketani S; Li Z; Liu L; Guo Y; Huang Y; Bowen AD; Liu M; Wang M; Yu J; Valdez R; Lauring AS; Sheng Z; Wang HH; Gordon A; Liu L; Ho DD
Cell; 2023 Jan; 186(2):279-286.e8. PubMed ID: 36580913
[TBL] [Abstract][Full Text] [Related]
20. Antigenic Characterization of Circulating and Emerging SARS-CoV-2 Variants in the U.S. throughout the Delta to Omicron Waves.
Di H; Pusch EA; Jones J; Kovacs NA; Hassell N; Sheth M; Lynn KS; Keller MW; Wilson MM; Keong LM; Cui D; Park SH; Chau R; Lacek KA; Liddell JD; Kirby MK; Yang G; Johnson M; Thor S; Zanders N; Feng C; Surie D; DeCuir J; Lester SN; Atherton L; Hicks H; Tamin A; Harcourt JL; Coughlin MM; Self WH; Rhoads JP; Gibbs KW; Hager DN; Shapiro NI; Exline MC; Lauring AS; Rambo-Martin B; Paden CR; Kondor RJ; Lee JS; Barnes JR; Thornburg NJ; Zhou B; Wentworth DE; Davis CT
Vaccines (Basel); 2024 May; 12(5):. PubMed ID: 38793756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
